Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
ClinicalTrials.gov study NCT07285382. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
ClinicalTrials.gov study NCT04922047. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
ClinicalTrials.gov study NCT01171417. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have R
ClinicalTrials.gov study NCT05853432. IPD Sharing: Not stated. Countries: 1. Publications: 0.
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06967103. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor
ClinicalTrials.gov study NCT05276713. IPD Sharing: NO. Countries: 1. Publications: 0.
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
ClinicalTrials.gov study NCT04316169. IPD Sharing: NO. Countries: 1. Publications: 0.
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
ClinicalTrials.gov study NCT01004081. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
ClinicalTrials.gov study NCT06671262. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
ClinicalTrials.gov study NCT05878314. IPD Sharing: NO. Countries: 1. Publications: 0.
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
ClinicalTrials.gov study NCT05759546. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
ClinicalTrials.gov study NCT05800756. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
ClinicalTrials.gov study NCT05297617. IPD Sharing: NO. Countries: 1. Publications: 0.
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
ClinicalTrials.gov study NCT05697146. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior
ClinicalTrials.gov study NCT06105632. IPD Sharing: YES. Countries: 14. Publications: 0.
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
ClinicalTrials.gov study NCT05067166. IPD Sharing: Not stated. Countries: 0. Publications: 11.
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
ClinicalTrials.gov study NCT04633902. IPD Sharing: NO. Countries: 1. Publications: 0.
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
ClinicalTrials.gov study NCT06344793. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period.
ClinicalTrials.gov study NCT02526927. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology
ClinicalTrials.gov study NCT04901351. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.